Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) major shareholder Claudius Llc sold 2,195,734 shares of the company’s stock in a transaction on Friday, December 14th. The shares were sold at an average price of $0.10, for a total transaction of $219,573.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Acura Pharmaceuticals, Inc. (OTCMKTS ACUR) opened at $0.41 on Friday. Acura Pharmaceuticals, Inc. has a twelve month low of $0.29 and a twelve month high of $1.40. The stock has a market cap of $8.32, a price-to-earnings ratio of -2.93 and a beta of 2.05. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.44.
Acura Pharmaceuticals (OTCMKTS:ACUR) last announced its quarterly earnings results on Monday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. Acura Pharmaceuticals had a negative return on equity of 231.18% and a negative net margin of 36.20%. The firm had revenue of $0.08 million for the quarter.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.